Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF
NCT04757584Phase 4Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carvedilol in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction at 36 weeks. Started Apr 2021; status: completed.
02
Drugs
carvedilol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04757584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757584.